Turkish Journal of Hematology Volume: 33 - Issue: 3

More documents

Recommendations

Info

Park YH, et al: BK Virus-Hemorrhagic Cystitis Turk J Hematol 2016;33:223-230 Table 4. Clinical characteristics of the patients receiving leflunomide therapy. Patient 1 Patient 2 Patient 3 Patient 4 Age (years)/Sex 40/M 49/M 50/F 52/M Diagnosis AML AML MDS AML Donor type MSD MSD MUD MSD Conditioning Bu/Flu Bu/Flu Bu/Flu Bu/Cy GVHD prophylaxis CsA/MTX CsA/MTX CsA/MTX CsA/MTX T-cell depletion No No Yes No Onset of BKV-HC (days) 24 21 19 23 Severity of HC Grade III Grade III Grade III Grade III Acute GVHD Grade II (skin) Grade II (skin, liver) Grade I (skin) Grade II (skin) Chronic GVHD Extensive Extensive Extensive Limited CMV antigenemia No Yes No No Response after therapy CR PR PR CR PCR positivity for BKV after therapy Positive Negative Positive Negative Adverse effects Nausea (mild) Nausea (mild) Abdominal bloating None Duration to response (days) 8 14 12 17 Outcome Alive Dead (due to leukemia Alive Alive relapse) M: Male, F: female, AML: acute myeloid leukemia, MDS: myelodysplastic syndrome, MSD: matched sibling donor, MUD: matched unrelated donor, Bu: busulfan, Flu: fludarabine, Cy: cyclophosphamide, CsA: cyclosporine, MTX: methotrexate, Allo-SCT: allogeneic stem cell transplantation, BKV-HC: BK virus hemorrhagic cystitis, GVHD: graft-versus-host disease, CMV: cytomegalovirus, CR: complete response, PR: partial response, PCR: polymerase chain reaction. Discussion Our results, with an overall incidence of HC following Allo-SCT of 43.5%, are consistent with other studies’ findings, which reported frequencies of HC following SCT ranging from 5% to 68% [3,4,5,6,7]. BKV was identified in 60.0% of cases (18 of 30 patients) by a qualitative PCR-based assay. A study of 22 Allo-SCT patients who experienced HC showed that the most frequent virus detected was BKV, with an incidence of 54.5% of patients, followed by JC virus and CMV [24]. In a study of 102 children who underwent Allo-SCT for malignancies and nonmalignant diseases, HC occurred in 26 patients (25.5%), and among them, BKV was identified in 21 (80.8%) patients [25]. These findings demonstrated that HC is a frequent complication after Allo-SCT and BKV is mainly responsible for HC in Allo-SCT recipients. Hemorrhagic cystitis after SCT frequently caused prolongation of hospitalization and occasionally death [10,24,26]. Gilis et al. demonstrated that the median duration of hospitalization for Allo-SCT was significantly longer for patients developing BKV-HC compared with those without BKV-HC (50 vs. 40 days, p
Turk J Hematol 2016;33:223-230 Park YH, et al: BK Virus-Hemorrhagic Cystitis of patients, respectively [21]. In a pilot study with five pediatric patients with severe BKV-HC after Allo-SCT, significantly shorter duration of BKV-HC (p
Page 1 and 2:
Volume 33 Issue 3 September 2016 80
Page 3 and 4:
Contact Information Editorial Corre
Page 5 and 6:
TURKISH JOURNAL OF HEMATOLOGY INSTR
Page 7 and 8:
have published research articles on
Page 9 and 10:
is provided. Each page has a “Get
Page 11 and 12:
251 A Case of Superwarfarin Poisoni
Page 13 and 14:
BİLİMSEL SEKRETERYA Kongre Sekret
Page 15 and 16:
Turk J Hematol 2016;33:172-179 Müg
Page 17 and 18:
Turk J Hematol 2016;33:172-179 Müg
Page 19 and 20: Turk J Hematol 2016;33:172-179 Müg
Page 21 and 22: Turk J Hematol 2016;33:172-179 Müg
Page 23 and 24: Turk J Hematol 2016;33:180-186 Wang
Page 29 and 30: RESEARCH ARTICLE DOI: 10.4274/tjh.2
Page 31 and 32: Turk J Hematol 2016;33:187-195 And
Page 39 and 40: Turk J Hematol 2016;33:196-201 Yama
Page 45 and 46: Turk J Hematol 2016;33:202-208 Iş
Page 53 and 54: Turk J Hematol 2016;33:209-215 Esba
Page 59 and 60: Turk J Hematol 2016;33:216-222 Yemi
Page 67 and 68: Turk J Hematol 2016;33:223-230 Park
Page 69: Turk J Hematol 2016;33:223-230 Park
Page 75 and 76: Turk J Hematol 2016;33:231-235 Özk
Page 77 and 78: Turk J Hematol 2016;33:231-235 Özk
Page 79 and 80: Turk J Hematol 2016;33:236-243 Yıl
Page 87 and 88: Turk J Hematol 2016;33:244-247 Akt
Page 89 and 90: Turk J Hematol 2016;33:244-247 Akt
Page 91 and 92: Turk J Hematol 2016;33:248-250 Alka
Page 93 and 94: BRIEF REPORT DOI: 10.4274/tjh.2015.
Page 95 and 96: Turk J Hematol 2016;33:251-253 Narl
Page 97 and 98: Turk J Hematol 2016;33:254-258 LETT
Page 99 and 100: Turk J Hematol 2016;33:254-258 LETT
Page 101 and 102: IMAGES IN HEMATOLOGY DOI: 10.4274/t
show all

Turkish Journal of Hematology Volume: 33 - Issue: 3

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?